//www.igerbera.com/journals/jamaneurology en-us Wed, 01 Mar 2023 00:00:00 GMT Mon, 13 Mar 2023 11:43:46 GMT Silverchair jamams@jamanetwork.org support@www.igerbera.com //www.igerbera.com/journals/jamaneurology/fullarticle/2802281 Wed, 01 Mar 2023 00:00:00 GMT Mission Statement: The mission of JAMA Neurology is to publish and disseminate scientific information primarily important for physicians caring for people with neurologic disorders and for those interested in the structure and function of the normal and diseased human nervous system. The specific aims are to (1) publish timely original research, including clinical trials that will directly improve clinical neurologic care and that will inform efforts to improve neurological health and promote health care equity; (2) report translational research that is pertinent to the understanding of neurologic disease; (3) address topics of practice, ethics, education, and public health that are a key part of modern medicine; and (4) provide a forum for discussion and publication of important topics including bias, racism, and diversity. This information will be published only after extensive review by scientific peers and journal editors so that clarity, rigor, originality, and precision are ensured. 80 3 224 224 10.1001/jamaneurol.2022.4073 2802281 //www.igerbera.com/journals/jamaneurology/fullarticle/2801290 Wed, 01 Mar 2023 00:00:00 GMT This cohort study investigates if concentrations of serum glial fibrillary acidic protein and neurofilament light chain are associated with and prognostic for disease progression in patients with multiple sclerosis. 80 3 287 297 10.1001/jamaneurol.2022.5250 2801290 //www.igerbera.com/journals/jamaneurology/fullarticle/2800416 Wed, 01 Mar 2023 00:00:00 GMT This randomized clinical trial investigates the effectiveness of a polypill in the reduction of cognitive and functional decline in individuals at intermediate risk of cardiovascular disease. 80 3 251 259 10.1001/jamaneurol.2022.5088 2800416 //www.igerbera.com/journals/jamaneurology/fullarticle/2800415 Wed, 01 Mar 2023 00:00:00 GMT This cohort study analyzes age- and sex-specific incidence rates of frontotemporal lobar degeneration–related disorders by phenotype across 9 European countries. 80 3 279 286 10.1001/jamaneurol.2022.5128 2800415 //www.igerbera.com/journals/jamaneurology/fullarticle/2800332 Wed, 01 Mar 2023 00:00:00 GMT This randomized clinical trial evaluates matching efficacy, safety, and immunogenicity between biosimilar natalizumab and reference natalizumab in patients with relapsing-remitting multiple sclerosis. 80 3 298 307 10.1001/jamaneurol.2022.5007 2800332 //www.igerbera.com/journals/jamaneurology/fullarticle/2800331 Wed, 01 Mar 2023 00:00:00 GMT This cohort study uses Atherosclerosis Risk in Communities study data to evaluate the association of head injury with long-term all-cause mortality risk in adults. 80 3 260 269 10.1001/jamaneurol.2022.5024 2800331 //www.igerbera.com/journals/jamaneurology/fullarticle/2800330 Wed, 01 Mar 2023 00:00:00 GMT This Viewpoint discusses recent efforts to update diagnostic criteria for cerebral amyloid angiopathy as well as questions and challenges in counseling patients about prognosis and deciding on optimal treatment. 80 3 225 226 10.1001/jamaneurol.2022.5060 2800330 //www.igerbera.com/journals/jamaneurology/fullarticle/2800168 Wed, 01 Mar 2023 00:00:00 GMT 这个随机临床试验评估efficacy of a web-based diagnosis and treatment of benign paroxysmal positional vertigo when it recurs in patients with confirmed and treated benign paroxysmal positional vertigo. 80 3 244 250 10.1001/jamaneurol.2022.4944 2800168 //www.igerbera.com/journals/jamaneurology/fullarticle/2800167 Wed, 01 Mar 2023 00:00:00 GMT In this essay, the author recounts caring for a patient from primary care clinic to hospice referral and attending the patient’s funeral. 80 3 229 230 10.1001/jamaneurol.2022.4957 2800167 //www.igerbera.com/journals/jamaneurology/fullarticle/2800166 Wed, 01 Mar 2023 00:00:00 GMT This narrative review discusses the management of rare trigeminal autonomic cephalalgias over the last 20 years. 80 3 308 319 10.1001/jamaneurol.2022.4804 2800166 //www.igerbera.com/journals/jamaneurology/fullarticle/2800165 Wed, 01 Mar 2023 00:00:00 GMT This Viewpoint discusses the challenges and opportunities of including patients with glioma in clinical trials. 80 3 227 228 10.1001/jamaneurol.2022.4924 2800165 //www.igerbera.com/journals/jamaneurology/fullarticle/2799840 Wed, 01 Mar 2023 00:00:00 GMT This case report describes remote video-based diagnosis and management of triple posttraumatic benign paroxysmal positional vertigo. 80 3 322 322 10.1001/jamaneurol.2022.4861 2799840 //www.igerbera.com/journals/jamaneurology/fullarticle/2799839 Wed, 01 Mar 2023 00:00:00 GMT This case series assesses the safety of an endovascular brain-computer interface and feasibility of using the system to control a computer by thought. 80 3 270 278 10.1001/jamaneurol.2022.4847 2799839 //www.igerbera.com/journals/jamaneurology/fullarticle/2799624 Wed, 01 Mar 2023 00:00:00 GMT 急性缺血性中风患者的近20%(AIS) are undergoing direct oral anticoagulant (DOAC) treatment at the time of their stroke. Common indications for DOACs among these patients include stroke prevention from atrial fibrillation, treatment of venous and pulmonary thrombosis, and coronary and peripheral atherosclerotic disease. Novel indications for DOAC use are expected to emerge and may increase the proportion of patients with AIS who are undergoing treatment with DOACs. Current US and European acute stroke treatment guidelines recommend withholding intravenous thrombolysis (thrombolysis), a morbidity- and mortality-saving AIS treatment for patients with recent a DOAC use. DOACs have emerged as preferred anticoagulants over vitamin K antagonists due to a favorable safety profile, particularly a lower risk of severe systemic and intracranial hemorrhage (ICH). However, if this translates into a lower risk of hemorrhagic complications of thrombolysis for AIS in the setting of DOAC treatment is yet to be definitively determined as data supporting this practice are limited and heterogenous. The present study by Meinel et al meaningfully advances the field by generating these critical data. Comparative analyses of different patient selection paradigms for thrombolysis in the presence of DOACs provide additional, timely relevance to the study. 80 3 231 232 10.1001/jamaneurol.2022.4765 2799624 //www.igerbera.com/journals/jamaneurology/fullarticle/2799623 Wed, 01 Mar 2023 00:00:00 GMT In this case report, a patient with Tourette syndrome was admitted to the emergency department with nonrhythmic, continuous, generalized hyperkinetic movements associated with muscle contractions in the trunk, neck, and upper and lower limbs caused by depletion of the deep brain stimulation battery. 80 3 320 321 10.1001/jamaneurol.2022.4774 2799623 //www.igerbera.com/journals/jamaneurology/fullarticle/2799622 Wed, 01 Mar 2023 00:00:00 GMT This cohort study evaluates the risk of symptomatic intracranial hemorrhage associated with use of intravenous thrombolysis in patients with recent direct oral anticoagulant ingestion. 80 3 233 243 10.1001/jamaneurol.2022.4782 2799622 //www.igerbera.com/journals/jamaneurology/fullarticle/2799621 Wed, 01 Mar 2023 00:00:00 GMT A 51-year-old man had severe neck pain and pustules on both hands. What is your diagnosis? 80 3 323 324 10.1001/jamaneurol.2022.4739 2799621

map